Physician profile
Jeffrey Scharstein
NPI 1588636161
$1,791.38
in general payments reported to CMS, 2019-2025
30 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $188 · 2021: $545 · 2022: $357 · 2023: $277 · 2024: $74.12 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.26 | 2020-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $261.00 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $130.14 | 2019-2023 | Farxiga |
| Sunovion Pharmaceuticals INC. | $93.74 | 2021 | |
| Xeris Pharmaceuticals, INC. | $84.44 | 2023-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $83.40 | 2019-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $74.21 | 2020-2021 | |
| Lilly USA, LLC | $68.86 | 2021-2024 | Jardiance, Trulicity, Mounjaro |
| Sanofi-Aventis U.S. LLC | $63.73 | 2021 | |
| Pfizer INC. | $61.30 | 2019-2024 | |
| Abbott Laboratories | $52.66 | 2021-2023 | Freestyle Libre 2 |
| Amgen INC. | $46.40 | 2019-2023 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $38.85 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $38.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $32.59 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $27.95 | 2023 | Gemtesa |
| Scilex Pharmaceuticals INC. | $25.05 | 2025 | |
| Urovant Sciences INC | $24.30 | 2022 | |
| Exact Sciences Corporation | $22.45 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.46 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $18.73 | 2023 | Rexulti |
| Boston Scientific Corporation | $18.27 | 2025 | Watchman Flx |
| Collegium Pharmaceutical, INC. | $17.98 | 2021 | |
| Lundbeck LLC | $16.90 | 2023 | Rexulti |
| Virtus Pharmaceuticals LLC | $14.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.70 | 2021 | |
| Radius Health, INC. | $14.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.10 | 2019 | |
| Cvrx, INC. | $13.07 | 2025 | Barostim Neo System |
| Forte Bio-Pharma LLC | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Scharstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.